Deal and investment activity remains critical to the success of life sciences and healthcare innovation.
Sidley once again brought together senior pharma, biotech, healthcare, private equity, and venture capital executives to share their perspectives on critical issues, trends, and opportunities.
Sidley and industry leaders from across the globe, including from AstraZeneca, BioCentury, Compass Pathways, Financial Times, Flagship Pioneering, IQVIA, J.P. Morgan, LetterOne Health, Mestag Therapeutics, Morgan Stanley, Novartis, Onex, Permira, Perspectum, Rothschild & Co., Sofinnova Partners, Syncona, SV Health Investors, and Teva joined together for this in-person, all-day event.
View the agenda here.
View confirmed speakers here.
Panels included:
- Private Equity – What is the outlook for PE investment activity across Healthcare and Life Sciences? Which domains will be the “winners”?
- Artificial Intelligence – To what extent, and where, does AI represent an investment opportunity across Healthcare and Life Sciences?
- Fireside Chat – “A Life in Pharma and Pivoting to Innovation”- A conversation with Richard Francis, President and CEO, Teva.
- A View From the Banks – Opinions, insights, and predictions on the market from a group of leading global healthcare dealmakers.
- Pharma Business Development – Senior BD and biotech figures debate the M&A, licensing, and collaboration climate. Which therapeutic areas and geographies are garnering the most attention?
- Venture/Growth Capital – How are global funds investing in a more muted market? How do investees stand out? Views from leading global life sciences investors.
For more information or questions, please contact lnevents@sidley.com.
SIDLEY HEALTHCARE INVESTMENT CONFERENCE 2023 HIGHLIGHTS